1) Ljungberg B, et al : EAU Guidelines on Renal Cell Carcinoma : The 2010 Update. Eur Urol 58 : 398-406, 2010
2) Ljungberg B, et al : EAU Guidelines on Renal Cell Carcinoma : 2014 Update. Eur Urol 67 : 913-924, 2015
3) Mickisch GH, et al : Radical Nephrectomy Plus Interferon-Alfa-Based Immunotherapy Compared With Interferon Alfa Alone in Metastatic Renal-Cell Carcinoma : A Randomised Trial. Lancet 358 : 966-970, 2001
4) Motzer RJ, et al : Interferon-alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. J Clin Oncol 20 : 289-296, 2002
5) Bex A, et al : Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol 74 : 805-809, 2018
6) Bex A, et al : Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib : The SURTIME Randomized Clinical Trial. JAMA Oncol 5 : 164-170, 2019
7) Méjean A, et al : Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 379 : 417-427, 2018
8) Takagi T, et al : Robot-Assisted Laparoscopic Versus Open Partial Nephrectomy in Patients With Chronic Kidney Disease : A Propensity Score-Matched Comparative Analysis of Surgical Outcomes. Int J Urol 24 : 505-510, 2017
9) Bex A, et al : Sunitinib Alone or After Nephrectomy in Renal Cancer. N Engl J Med 379 : 1877-1878, 2018
10) Motzer RJ, et al : Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378 : 1277-1290, 2018
11) Rini BI, et al : Pembrolizumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380 : 1116-1127, 2019
12) Motzer RJ, et al : Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380 : 1103-1115, 2019